Nilemdo

Organon has partnered with Daiichi Sankyo Europe to distribute Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland, and Norway. This collaboration aims to increase patient access to Nilemdo®, a novel treatment for high cholesterol and cardiovascular disease risk, especially for those intolerant to statins. Organon will handle distribution and promotion, supporting its cardiovascular portfolio and addressing unmet patient needs, particularly for women who often experience statin intolerance.